adamantane-1-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide | 911055-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: adamantane-1-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide
• 英文别名: N-[2-(1-methylpyrrolidin-2-yl)ethyl]adamantane-1-carboxamide
• CAS: 911055-90-8
• 化学式: C₁₈H₃₀N₂O
• 分子量: 290.449
• InChiKey: AHLBGWIRQOGHAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors
  申请人：Vicker Nigel

  公开号：US20090042929A1

  公开（公告）日：2009-02-12

  There is provided a compound having Formula (I) R 1 -Z-R 2 wherein R 1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R 2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R 2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula —C(═O)—CR 3 R 4 —X—(CR 5 R 6 )n-, wherein X is selected from NR 7 , S, O, S═O, and S(═O) 2 , wherein n is 0 or 1 and/or (c) R 1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R 1 is an adamantyl group and Z is or comprises a group of the formula —(CR 8 R 9 )p-NR 10 —S(═O) 2 —(CR 11 R 12 )q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R 1 is an adamantyl group and Z is or comprises a group of the formula —(CR 13 R 14 )V—Y—(CR 15 R 16 )W— where Y is a heteroaryl group in which a bond in the heteroaryl ring is a isostere of a carbonyl group, wherein v is o or 1 and w is 0 or 1; wherein each of R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 , are independently selected from H, hydrocarbyl and halogen, wherein each of R 7 and R 10 are independently selected from H and hydrocarbyl.

  提供一种化合物，其化学式为(I) R1-Z-R2，其中R1是选自可选取代的融合多环基团、取代的烷基基团、支链烷基基团和可选取代的环烷基基团的基团；Z是一个连接基团，可以是或包含一个羰基基团或一个羰基基团的同分异构体；R2是选自可选取代的芳香环和可选取代的杂环；其中(a) R2是2-取代噻吩基团，和/或(b) Z是一个化学式为—C(═O)—CR3R4—X—(CR5R6)n-的基团，其中X选自NR7、S、O、S═O和S(═O)2，n为0或1，和/或(c) R1是一个金刚烷基团，Z是或包含一个酰胺基团，和/或(d) R1是一个金刚烷基团，Z是或包含一个化学式为—(CR8R9)p-NR10—S(═O)2—(CR11R12)q-的基团，其中p为0或1，q为0或1，和/或(e) R1是一个金刚烷基团，Z是或包含一个化学式为—(CR13R14)V—Y—(CR15R16)W—的基团，其中Y是一个杂环基团，在杂环环中的一个键是羰基基团的同分异构体，v为0或1，w为0或1；其中R3、R4、R5、R6、R8、R9、R11、R12、R13、R14、R15和R16各自独立地选自H、烃基和卤素，R7和R10各自独立地选自H和烃基。
• Sphingosine Kinase Inhibitors
  申请人：Smith Charles D.

  公开号：US20080167352A1

  公开（公告）日：2008-07-10

  The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  本发明涉及置换的金刚烷化合物，其药物组成物、制备过程以及抑制鞘氨醇激酶、治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。
• Compound
  申请人：Vicker Nigel

  公开号：US20100120789A1

  公开（公告）日：2010-05-13

  There is provided a compound having Formula I R 1 —Z—R 2 Formula I wherein R 1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycloalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R 2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R 2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula —C(═O)—CR 3 R 4 —X—(CR 5 R 6 )n-, wherein X is selected from NR 7 , S, O, S═O, and S(═O) 2 , wherein n is 0 or 1 and/or (c) R 1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R 1 is an adamantyl group and Z is or comprises a group of the formula —(CR 8 R 9 )p- NR 10 —S(═O) 2 —(CR 11 R 12 )q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R 1 is an adamantyl group and Z is or comprises a group of the formula —(CR 13 R 14 )v-Y—(CR 15 R 16 )w- where Y is a heteroaryl group in which a bond in the heteroaryl ring is a isostere of a carbonyl group, wherein v is o or 1 and w is 0 or 1; wherein each of R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 , are independently selected from H, hydrocarbyl and halogen, wherein each of R 7 and R 10 are independently selected from H and hydrocarbyl.

  提供了一种具有IR1-Z-R2式的化合物，其中： R1是从可选取代的融合多环基团，取代的烷基基团，分支烷基基团和可选取代的环烷基基团中选择的基团； Z是或包括一个羰基或羰基的同分异构体的连接基团； R2是从可选取代的芳香环和可选取代的杂环中选择的基团，其中 (a) R2是2-取代噻吩基团，和/或 (b) Z是公式-C（═O）-CR3R4-X-（CR5R6）n-的基团，其中X从NR7，S，O，S═O和S（═O）2中选择，n为0或1，和/或 (c) R1是金刚烷基团，Z是或包括酰胺基团，和/或 (d) R1是金刚烷基团，Z是或包括公式-CR8R9p-NR10-S（═O）2-（CR11R12）q-的基团，其中p为0或1，q为0或1，和/或 (e) R1是金刚烷基团，Z是或包括公式（CR13R14）v-Y-（CR15R16）w-的基团，其中Y是杂环基团，其中杂环环中的一个键是羰基的同分异构体，v为0或1，w为0或1； 其中R3，R4，R5，R6，R8，R9，R11，R12，R13，R14，R15和R16中的每一个独立选择自H，烃基和卤素，其中R7和R10各自独立选择自H和烃基。
• Sphingosine kinase inhibitors
  申请人：Apogee Biothechnology Corporation

  公开号：EP2314574A1

  公开（公告）日：2011-04-27

  The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  本发明涉及取代的金刚烷化合物、其药物组合物、其制备工艺以及抑制鞘氨醇激酶和治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。
• Combination therapies for treating cancer
  申请人：RedHill Biopharma Ltd.

  公开号：US10463654B2

  公开（公告）日：2019-11-05

  Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.

  本发明提供了通过施用至少一种选自氯法齐明、利福布汀和克拉霉素组成的组的抗生素与芳基金刚烷化合物联合治疗患者癌症的方法。在一个实施方案中，芳基金刚烷化合物是[3-(4-氯苯基)-金刚烷-1-羧酸(吡啶-4-基甲基)酰胺]或其药学上可接受的盐。